Healthcare provider profile · identity verified

Giancarlo Lembo, MD

Family Practice · HIGHLAND, CA · NPI 1730423328

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	436	203
Ozempic	Semaglutide	199	35
Losartan Potassium	Losartan Potassium	160	75
Lisinopril	Lisinopril	153	73
Metformin Hcl	Metformin Hcl	144	71
Amlodipine Besylate	Amlodipine Besylate	141	73
Meloxicam	Meloxicam	138	68
Rosuvastatin Calcium	Rosuvastatin Calcium	135	63
Levothyroxine Sodium	Levothyroxine Sodium	130	56
Omeprazole	Omeprazole	130	68
Tamsulosin Hcl	Tamsulosin Hcl	102	50
Glipizide	Glipizide	98	47
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	84	19
Metformin Hcl Er	Metformin Hcl	83	38
Gabapentin	Gabapentin	75	40
Atenolol	Atenolol	70	33
Pantoprazole Sodium	Pantoprazole Sodium	70	44
Alendronate Sodium	Alendronate Sodium	58	34
Simvastatin	Simvastatin	58	27
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	57	28
Finasteride	Finasteride	56	25
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	54	28
Bisoprolol Fumarate	Bisoprolol Fumarate	52	20
Trazodone Hcl	Trazodone Hcl	51	26
Furosemide	Furosemide	49	26
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	47	26
Albuterol Sulfate Hfa	Albuterol Sulfate	43	34
Hydrochlorothiazide	Hydrochlorothiazide	41	21
Metoprolol Tartrate	Metoprolol Tartrate	36	19
Potassium Chloride	Potassium Chloride	35	21
Famotidine	Famotidine	34	21
Carvedilol	Carvedilol	33	14
Ibuprofen	Ibuprofen	33	22
Terazosin Hcl	Terazosin Hcl	31	15
Clopidogrel	Clopidogrel Bisulfate	29	14
Humulin 70/30 Kwikpen	Insulin Nph Hum/Reg Insulin Hm	28	12
Pradaxa	Dabigatran Etexilate Mesylate	28	16
Cephalexin	Cephalexin	27	23
Prednisone	Prednisone	27	21
Hydralazine Hcl	Hydralazine Hcl	24	11
Jardiance	Empagliflozin	24	13
Duloxetine Hcl	Duloxetine Hcl	23	12
Hydrocortisone	Hydrocortisone	23	13
Montelukast Sodium	Montelukast Sodium	23	11
Nystatin	Nystatin	23	14
Ondansetron Odt	Ondansetron	23	11
Adacel Tdap	Diph,pertuss(Acell),tet Vac/Pf	21	21
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	21	suppressed
Sumatriptan Succinate	Sumatriptan Succinate	21	suppressed
Diazepam	Diazepam	20	suppressed
Humulin N Kwikpen	Insulin Nph Human Isophane	20	suppressed
Insulin Glargine-Yfgn	Insulin Glargine-Yfgn	20	11
Triamcinolone Acetonide	Triamcinolone Acetonide	18	12
Dicyclomine Hcl	Dicyclomine Hcl	17	suppressed
Humulin N	Insulin Nph Human Isophane	17	suppressed
Lactulose	Lactulose	16	suppressed
Sertraline Hcl	Sertraline Hcl	16	suppressed
Trospium Chloride	Trospium Chloride	16	suppressed
Metronidazole	Metronidazole	15	suppressed
Nitroglycerin	Nitroglycerin	15	suppressed
Pioglitazone Hcl	Pioglitazone Hcl	15	suppressed
Spiriva Respimat	Tiotropium Bromide	15	suppressed
Spironolactone	Spironolactone	15	suppressed
Veo Insulin Syringe	Syringe And Needle,insulin,1ml	15	suppressed
Allopurinol	Allopurinol	14	suppressed
Azelastine Hcl	Azelastine Hcl	14	suppressed
Cyclosporine	Cyclosporine	14	suppressed
Pravastatin Sodium	Pravastatin Sodium	14	suppressed
Ezetimibe	Ezetimibe	13	suppressed
Veo Insulin Syringe	Syrge-Ndl,ins 0.3 Ml Half Mark	13	suppressed
Citalopram Hbr	Citalopram Hydrobromide	12	suppressed
Eliquis	Apixaban	12	suppressed
Glipizide Er	Glipizide	12	suppressed
Humulin 70-30	Insulin Nph Hum/Reg Insulin Hm	12	suppressed
Humulin R	Insulin Regular, Human	12	suppressed
Veltassa	Patiromer Calcium Sorbitex	12	suppressed
Amoxicillin	Amoxicillin	11	suppressed
Fluconazole	Fluconazole	11	11
Isosorbide Mononitrate Er	Isosorbide Mononitrate	11	suppressed
Latanoprost	Latanoprost	11	suppressed
Valacyclovir	Valacyclovir Hcl	11	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error